ABSTRACT
Introduction. Rubella is a worldwide contagious disease with self-limited symptoms and a generalized rash. Epidemiology of rubella changed after licensing the vaccine in 1969. Children’s rubella is a self-limited infection, but when it occurs during pregnancy, there is a risk of severe damage to the fetus.
Objectives. The aim of this study was to determine the immunity against rubella virus in pregnant women in Pleven Region, Bulgaria.
Methods. A cross-sectional study was carried out on pregnant women hospitalized in a Clinic of obstetrics and gynecology, University Hospital-Pleven, Bulgaria. Quantitative determination of specific Immunoglobulin G (IgG) antibodies against rubella virus was performed by Enzyme-Like Immunosorbent Assay (ELISA). Data were analyzed using the Microsoft Office Excel 2007 software.
Results. Between January 2018 and December 2018 there were collected and tested to Rubella virus IgG antibody 242 serum samples. Two hundred and four (84.30%) of them were positive, 29 (11.98%) were negative and 9 (3.72%) – equivocal. The age of examined women was between 14 and 45 years, average 27, sd±6.429. We found high seropositivity within age group 21-30 years of age. The immunization status of the investigated women shows – unimmunized – 79, selectively immunized with one dose of monovaxin – 58, immunized with combined (measles, mumps, rubella) vaccine one dose – 82, with a double immunization schedule – 23. In each group there were seropositive women.
Conclusions. Data analysis shows that pregnant women have high immunity and a tendency for lower morbidity rates of acute rubella infection.
Keywords: rubella immunity, pregnancy, immunoglobulin G antibodies.
Full text sources https://doi.org/10.31688/ABMU.2019.54.4.06 How to cite Email to Author Format XML
Address for correspondence:
Milena KARCHEVA
Department of Epidemiology, Parasitology and Tropical Medicine, Medical University-Pleven, Bulgaria
Address: Sv. Kliment Ohridski Str.no.1, 5800 Pleven, Bulgaria
Email: milena_karcheva@abv.bg; Phone: +35 964 884 208
